Showing 4331-4340 of 5627 results for "".
- Iveric Bio Completes Patient Enrollment of GATHER2 Pivotal Clinical Trial of Zimura Ahead of Schedulehttps://modernod.com/news/iveric-bio-completes-patient-enrollment-of-gather2-pivotal-clinical-trial-of-zimura-ahead-of-schedule-2/2479422/Iveric bio announced the early completion of patient enrollment of GATHER2, the company’s second pivotal clinical trial of Zimura (avacincaptad pegol) in development for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The company expects topline GATHE
- Ocular Therapeutix Announces First Patient Dosed in US-Based Phase 1 Trial of OTX-TKI for Wet AMDhttps://modernod.com/news/ocular-therapeutix-announces-first-patient-dosed-in-us-based-phase-1-clinical-trial-of-otx-tki-for-the-treatment-of-wet-amd/2479421/Ocular Therapeutix announced that it has dosed the first patient in the United States phase 1 clinical trial of OTX-TKI (axitinib intravitreal implant) for the treatment of wet age-related macular degeneration (AMD). “We are very excited to have recently begu
- FDA Accepts Application for Genentech’s Faricimab for the Treatment of Wet AMD and DMEhttps://modernod.com/news/fda-accepts-application-for-genentechs-faricimab-for-the-treatment-of-wet-amd-and-dme/2479419/Genentech announced that the FDA has accepted the company’s Biologics License Application (BLA), under Priority Review, for faricimab for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME). The FDA has also accepted the company’s submission for diabetic r
- Aurion Biotech Announces IOTA Cell Therapy Trialhttps://modernod.com/news/aurion-biotech-announces-iota-cell-therapy-trial/2479415/Aurion Biotech announced preliminary findings from its IOTA trial, conducted in November 2020 and in May of this year, at the Clínica Quesada in San Salvador, El Salvador. In the IOTA trial, 50 patients diagnosed with corneal endothelial disease were treated with a transformational cell th
- Iveric Bio Completes Patient Enrollment of GATHER2 Pivotal Clinical Trial of Zimura Ahead of Schedulehttps://modernod.com/news/iveric-bio-completes-patient-enrollment-of-gather2-pivotal-clinical-trial-of-zimura-ahead-of-schedule/2479414/Iveric bio announced the early completion of patient enrollment of GATHER2, the company’s second pivotal clinical trial of Zimura (avacincaptad pegol) in development for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The company expects topline GATHE
- Allegro Announces Positive Results of Vehicle-Controlled Ex-US Phase 2 Trial of ALG-1007 for the Treatment of Dry Eye Diseasehttps://modernod.com/news/allegro-announces-positive-results-of-vehicle-controlled-ex-us-phase-2-trial-of-alg-1007-for-the-treatment-of-dry-eye-disease/2479410/Allegro Ophthalmics announced that all primary and secondary endpoints of an ex-US vehicle-controlled study of ALG-1007 topical eye drop in patients with dry eye disease (DED) were met. The results were presented by Eric D. Donnenfeld, MD, at the 2021 American Society of Cataract and Refractive S
- BVI Announces Collaboration With BeyeOnics Visionhttps://modernod.com/news/bvi-announces-collaboration-with-beyeonics-vision/2479411/BVI announces a collaboration with Israel-based BeyeOnics Vision, a maker of in head-mounted display, digital data, and imaging processing. BeyeOnics Vision has been developing BeyeOnics 1, which the company describes as the first and only ophthalmic digital imaging system replacing the op
- Glaukos Comments on the CMS 2022 Proposed Physician Fee Schedulehttps://modernod.com/news/glaukos-comments-on-the-cms-2022-proposed-physician-fee-schedule/2479412/Glaukos commented on the recently released Centers for Medicare and Medicaid Services (CMS) Calendar Year 2022 Medicare Physician Fee Schedule Proposed Rule. The Proposed Rule was released on July 13, 2021, and updates payment policies, payment rates and other provisions for services furnished un
- LumiThera: Data Show Valeda Treatments Improve Vision and Retinal Function in Dry AMD patientshttps://modernod.com/news/lumithera-data-show-valeda-treatments-improve-vision-and-retinal-function-in-dry-amd-patients/2479408/LumiThera, a commercial stage medical device company offering a photobiomodulation (PBM) treatment for ocular damage and disease, announced the final topline data from the ELECTROLIGHT pilot study in intermediate dry AMD patients. A total of 23 eyes from 15 subjects with dry AMD were enro
- Scientists Discover Gene Therapy Provides Neuroprotection to Prevent Glaucoma Vision Losshttps://modernod.com/news/scientists-discover-gene-therapy-provides-neuroprotection-to-prevent-glaucoma-vision-loss/2479407/A form of gene therapy protects optic nerve cells and preserves vision in mouse models of glaucoma, according to research supported by NIH’s National Eye Institute. The findings suggest a way forward for developing neuroprotective therapies for glaucoma, a leading cause of visual impairment and b